The tumour-targeting immunocytokine F16-IL2 in combination with doxorubicin: dose escalati

Chiara Catania authored a clinical trial dataset from a phase Ib/II study evaluating the combination of the immunocytokine F16-IL2 with doxorubicin. The dataset includes results from 29 patients (19 with progressive solid tumors, 10 with metastatic breast cancer) across escalating dose cohorts. It reports safety, tolerability, pharmacokinetics, and disease control rates over 8 and 12 weeks.

Use Cases

• Analyze dose-dependent pharmacokinetics based on the reported half-lives of F16-IL2 at different dose levels
• Model disease control rates over time based on the reported 57% and 67% rates at 8 weeks for Phase I and II cohorts
• Assess safety profiles for drug combinations based on the reported toxicities and absence of treatment-related deaths
• Investigate patient response duration based on the reported case of a 45-week partial response

Strengths

• Includes data from 29 patients across two distinct trial phases
• Reports specific disease control rates (57% and 67% at 8 weeks) for evaluable patient groups
• Provides concrete pharmacokinetic data, including half-lives of approximately 13 and 8 hours for different dose cohorts
• Specifies precise dose ranges for both F16-IL2 (5-25 MIU) and doxorubicin (0-25mg/m²)

Limitations

• Row count and column-level documentation are unknown; field semantics must be inferred after download
• Last update date is unknown; freshness unverified
• Data may reflect the specific patient population and trial design bias inherent to paperswithcode

Provenance

Source

Chiara Catania via paperswithcode

Collection Method

Data collected from a clinical phase Ib/II trial